Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improve in vitro dissolution and in vivo oral absorption

Drug Development and Industrial Pharmacy

Volumn 38, Issue 8, 2012, Pages 1015-1023

  Tanaka, Yusuke ^a,b   Inkyo, Mitsugi ^c   Yumoto, Ryoko ^b   Nagai, Junya ^b   Takano, Mikihisa ^b   Nagata, Shunji ^a  

^a HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Kotobuki Industries Co Ltd   (Japan)

Author keywords

Gelcire; Nanoparticle; Nanotechnology; Pluronic; Vitamine E TPGS

Indexed keywords

GELUCIRE; GELUCIRE 44 14; GELUCIRE 50 13; NANOPARTICLE; PLURONIC F 108; POLOXAMER; PROBUCOL; TOCOFERSOLAN; UNCLASSIFIED DRUG; ZIRCONIUM;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG FORMULATION; DRUG SOLUBILITY; MALE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; RAT; ROTATION; WET MILLING PROCESS;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; DRUG COMPOUNDING; MALE; NANOPARTICLES; PARTICLE SIZE; POWDERS; PROBUCOL; RATS; RATS, WISTAR; SOLUBILITY; WATER;

EID: 84863450309     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.637051     Document Type: Article

References (54)

1. Lipinski CA. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods, 44:235-249.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 46:3-26.
3. Lipinski CA. (2002). Poorly aqueous solubility: An industry wide problem in drug discovery. Am Pharm Rev, 5:82-85.
4. Liversidge GG, Cundy KC. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91-97.
5. Jan M, Georgr A, Herberk P, Rainer HM. (2004). Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm, 58:615-619.
6. Rogers TL, Gillespie IB, Hitt JE, Fransen KL, Crowl CA, Tucker CJ et al. (2004). Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm Res, 21:2048-2057.
7. Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113-120.
8. Mittapalli PK, Yamasani MR, Shashank A. (2007). Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Current Nanoscience, 3:191-194.
9. Mittapalli PK, Yamasani MR, Shashank A. (2008). Formulation of nanosuspensions of albendazole for oral administration. Current Nanoscience, 4:53-58.
10. Onoue S, Sato H, Ogawa K, Kawabata Y, Mizumoto T, Yuminoki K et al. (2010). Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach. Int J Pharm, 399:94-101.
11. Niwa T, Miura S, Danjo K. (2011). Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies-Development of particle design method. Int J Pharm, 405:218-227.
12. Inkyo M, Tahara T. (2004). Dispersion of agglomerated nanoparticles by fne beads mill. J Soc Powder Technol, Japan, 41:578-585.
13. Inkyo M. (2005). Dispersion Technology Book. Tokyo: Johokiko Co. Ltd. pp 73-86.
14. Braun A, Zhang S, Miettinen HE, Ebrahim S, Holm TM, Vasile E et al. (2003). Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci USA, 100:7283-7288.
15. Hong SC, Zhao SP, Liu Q, Wu ZH. (2008). Efect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits. Int J Cardiol, 123:180-182.
16. Heeg JF, Hiser MF, Satonin DK, Rose JQ. (1984). Pharmacokinetics of probucol in male rats. J Pharm Sci, 73:1758-1763.
17. Shudo J, Pongpeerapat A, Wanawongthai C, Moribe K, Yamamoto K. (2008). In vivo assessment of oral administration of probucol nanoparticles in rats. Biol Pharm Bull, 31:321-325.
18. Yagi N, Terashima Y, Kenmotsu H, Sekikawa H. (1996). Dissolution behavior of probucol from solid dispersion systems of probucolpolyvinylpyrrolidone. Chem Pharm Bull, 44:241-244.
19. Betge S, Lutz K, Roskos M, Figulla HR. (2007). Oral treatment with probucol in a pharmacological dose has no benefcial efects on mortality in chronic ischemic heart failure after large myocardial infarction in rats. Eur J Pharmacol, 558:119-127.
20. Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S. (2009). Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders. Chem Pharm Bull, 57:1050-1057.
21. Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S. (2010). Evaluation of in vitro dissolution and in vivo oral absorption of drug nanopowders prepared by novel wet-milling equipment. Current Nano Science, 6:571-576.
22. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. (1998). Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res, 15:698-705.
23. Dressman JB, Reppas C. (2000). In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11 Suppl 2:S73-S80.
24. Kabanov AV, Alakhov VY. (2002). Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifers. Crit Rev Ter Drug Carrier Syst, 19:1-72.
25. Rahme K, Oberdisse J, Schweins R, Gaillard C, Marty JD, Mingotaud C et al. (2008). Pluronics-stabilized gold nanoparticles: Investigation of the structure of the polymer-particle hybrid. Chemphyschem, 9:2230-2236.
26. Gao L, Zhang D, Chen M, Zheng T, Wang S. (2007). Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm, 33:1332-1339.
27. Zhang L, Chai G, Zeng X, He H, Xu H, Tang X. (2010). Preparation of fenofbrate immediate-release tablets involving wet grinding for improved bioavailability. Drug Dev Ind Pharm, 36:1054-1063.
28. Sigfridsson K, Lundqvist AJ, Strimfors M. (2009). Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm, 35:1479-1486.
29. Liu Y, Kathan K, Saad W, Prud'homme RK. (2007). Ostwald ripening of β-carotene nanoparticles. Phys Rev Lett, 98:036102.
30. Cartwright JH, Piro O, Tuval I. (2009). Ostwald ripening, chiral crystallization, and the common-ancestor efect. Drug Dev Ind Pharm, 35:1479-1486.
31. Bastús NG, Comenge J, Puntes V. (2011). Kinetically controlled seeded growth synthesis of citrate-stabilized gold nanoparticles of up to 200 nm: Size focusing versus Ostwald ripening. Langmuir, 27:11098-11105.
32. Wu W, Zhang S, Zhou J, Xiao X, Ren F, Jiang C. (2011). Controlled synthesis of monodisperse sub-100 nm hollow SnO2 nanospheres: A template-and surfactant-free solution-phase route, the growth mechanism, optical properties, and application as a photocatalyst. Chemistry, 17:9708-9719.
33. Kattige A, Rowley G. (2006). The efect of poloxamer viscosity on liquid-flling of solid dispersions in hard gelatin capsules. Drug Dev Ind Pharm, 32:981-990.
34. Brochure Gelucire® 44/14. 1st Edition. Gattefosse S.A. (1999).
35. Brochure Gelucire® 50/13. 1st Edition. Gattefosse. S.A. (1999)
36. Brochure Eastman Vitamin E TPGS NF. Eastman Chemical Company. (1998).
37. Kim KR, Ahn KY, Park JS, Lee KE, Jeon H, Lee J. (2011). Lyophilization and enhanced stability of fuorescent protein nanoparticles. Biochem Biophys Res Commun, 408:225-229.
38. Hafner A, Dürrigl M, Pepic I, Filipovic-Grcic J. (2011). Short-and long-term stability of lyophilised melatonin-loaded lecithin/chitosan nanoparticles. Chem Pharm Bull, 59:1117-1123.
39. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev, 58:1688-1713.
40. Cho E, Cho W, Cha KH, Park J, Kim MS, Kim JS, Park HJ, Hwang SJ. (2010). Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives. Int J Pharm, 396:91-98.
41. Jarmer DJ, Lengsfeld CS, Anseth KS, Randolph TW. (2005). Supercritical fuid crystallization of griseofulvin: Crystal habit modifcation with a selective growth inhibitor. J Pharm Sci, 94:2688-2702.
42. Liversidge GG, Phillips CP, Cundy KC. (1994). US patent US 5302401 (1994).
43. Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, Van den Mooter G. (2007). Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-efects of formulation parameters on physicochemical stability. Int J Pharm, 338:198-206.
44. Konan YN, Gurny R, Allémann E. (2002). Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 233:239-252.
45. Lindahl A, Ungell AL, Knutson L, Lennernäs H. (1997). Characterization of fuids from the stomach and proximal jejunum in men and women. Pharm Res, 14:497-502.
46. Vertzoni M, Fotaki N, Kostewicz E, Stippler E, Leuner C, Nicolaides E et al. (2004). Dissolution media simulating the intralumenal composition of the small intestine: Physiological issues and practical aspects. J Pharm Pharmacol, 56:453-462.
47. McConnell EL, Fadda HM, Basit AW. (2008). Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm, 364:213-226.
48. Overhof KA, McConville JT, Yang W, Johnston KP, Peters JI, Williams RO 3rd. (2008). Efect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res, 25: 167-175.
49. Pandit N, Trygstad T, Croy S, Bohorquez M, Koch C. (2000). Efect of Salts on the Micellization, Clouding, and Solubilization Behavior of Pluronic F127 Solutions. J Colloid Interface Sci, 222: 213-220.
50. Khutoryanskiy VV, Mun GA, Nurkeeva ZS, Dubolazov AV. (2004). pH and salt efects on interpolymer complexation via hydrogen bonding in aqueous solutions. Polym Int, 53:1382-1387.
51. Comba S, Sethi R. (2009). Stabilization of highly concentrated suspensions of iron nanoparticles using shear-thinning gels of xanthan gum. Water Res, 43:3717-3726.
52. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y et al. (2006). Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res, 23:1144-1156.
53. Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y et al. (2008). Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res, 25:2334-2344.
54. Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, Machida M, Aso Y, Yamashita S. (2010). Quantitative analysis of the efect of supersaturation on in vivo drug absorption. Mol Pharm, 7:1431-1440.